G-CSF (Nuopogen, Amgen Inc.) is FDA approved for progenitor/stem cell mobilization. It has been used clinically as stand-alone neovascularization therapy. Investigators will use it in this protocol to correct the deficiency in this vital cell population in CLI patients, enhancing arteriogenesis and angiogenesis. Investigators will measure its biochemical impact.